Welcome to our dedicated page for Logicbio Therapeutics news (Ticker: LOGC), a resource for investors and traders seeking the latest updates and insights on Logicbio Therapeutics stock.
ContextLogic Holdings Inc. reports developments as a publicly traded business ownership platform focused on acquiring and building a portfolio of niche, competitively advantaged, long-duration businesses. News about ContextLogic centers on the completed acquisition of US Salt, operating and financial results, acquisition strategy, cash and investment resources, and the company’s evolution into a portfolio ownership model.
Company updates also cover governance and capital-structure matters, including board appointments, audit committee membership, shareholder voting, Delaware reorganization actions, strategic investment arrangements, and securities registration matters. The recurring themes are portfolio ownership, acquisition execution, operating efficiency, and public-company governance.
LogicBio Therapeutics (Nasdaq: LOGC) announced that CEO Frederic Chereau will participate in a panel at the 2021 Redburn Gene Therapy Summit on March 31, 2021, at 9:15 a.m. EDT. The panel, titled "Gene therapy: a changing regulatory landscape," will feature discussions on LogicBio's innovative gene delivery and gene editing platforms, specifically the SUNRISE clinical trial of LB-001, aimed at treating methylmalonic acidemia (MMA). LogicBio is pioneering new technologies for addressing rare diseases.
LogicBio Therapeutics (LOGC) reported its financial results for 2020, revealing a net loss of $32.6 million or $1.29 per share, an improvement from $40.1 million or $1.78 per share in 2019. R&D expenses decreased to $22.8 million, primarily due to reduced external development costs for LB-001. General administrative expenses rose to $12.2 million. The company holds $70.1 million in cash, expected to support operations for the next twelve months. LogicBio anticipates the first patient enrollment in the SUNRISE trial for LB-001 soon, aiming to generate valuable clinical data.
LogicBio Therapeutics (Nasdaq:LOGC), a clinical-stage genetic medicine company, announced that CEO Frederic Chereau will present at two upcoming investor conferences. He will present at the Barclays Global Healthcare Conference on March 11, 2021, at 4:10 p.m. ET. Additionally, he will record a presentation for the H.C. Wainwright Global Life Sciences Conference, available online from March 9-10, 2021. LogicBio focuses on innovative gene delivery and editing platforms to treat rare diseases, utilizing the GeneRide and sAAVy platforms for effective gene therapy development.
LogicBio Therapeutics (Nasdaq: LOGC) has expanded its research partnership with Children's Medical Research Institute (CMRI) to develop next-generation adeno-associated virus (AAV) vectors. This collaboration aims to enhance gene therapy and gene editing for liver diseases and other tissues. The partnership follows successful research efforts, including the anticipated enrollment of patients in the SUNRISE Phase I/II clinical trial for LB-001, targeting methylmalonic acidemia. LogicBio's GeneRide technology and new AAV capsids present broad therapeutic potential, advancing the company's pipeline.
LogicBio Therapeutics (Nasdaq: LOGC) announced that CEO Fred Chereau will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 4:30 pm ET. The presentation will cover company operations, including its GeneRide genome editing platform and next-generation synthetic capsids. A live audio webcast will be accessible on LogicBio's website, with a replay available within 24 hours. The company is advancing its LB-001 program for methylmalonic acidemia and collaborating with Takeda on LB-301 for Crigler-Najjar syndrome.
LogicBio Therapeutics announced the appointment of Cecilia Jones as the new chief financial officer, effective January 11, 2021. She replaces Matthias Jaffe, who will continue as a consultant. Jones brings over 20 years of experience, formerly serving at Biogen and Genzyme. The company is entering a significant growth phase, with the initiation of a phase 1/2 clinical trial for LB-001 targeting methylmalonic acidemia and a successful public offering. CEO Fred Chereau expressed optimism about Jones's role in future opportunities for the company.
LogicBio Therapeutics (Nasdaq: LOGC) announced the appointment of Daphne Karydas and Jeff Goater to its board of directors, enhancing its strategic leadership in the biopharma sector. Karydas, CFO at Syndax, brings extensive finance experience from Allergan and investment banking. Goater, CEO at Surface Oncology, has a strong background in guiding biotech firms through IPOs and strategic partnerships. The company is set to advance its pipeline, including the upcoming phase 1/2 SUNRISE clinical trial for LB-001. The board also acknowledged departing members Erez Chimovits and Daniel O'Connell for their contributions.
LogicBio Therapeutics (Nasdaq:LOGC) announced key presentations at upcoming investor conferences. COO Kyle Chiang will participate in a fireside chat at the Barclay's Gene Editing and Gene Therapy Summit on November 16, 2020. CEO Frederic Chereau is set to present at the Jeffries Virtual London Healthcare Conference on November 19, 2020, and will also record a session for the Piper Sandler Virtual Healthcare Conference, available from November 30, 2020. The company focuses on advancing genetic medicine with its GeneRide technology, and has received FDA clearance for its first clinical trial of LB-001.
LogicBio Therapeutics (Nasdaq: LOGC) reported its Q3 2020 financial results, marking several critical developments in its LB-001 program for methylmalonic acidemia (MMA). The company cleared the IND for LB-001 in August 2020 and received Fast Track designation in November 2020. R&D expenses decreased to $5.5 million, while G&A expenses rose to $3.2 million. The net loss narrowed to $8.0 million, or $0.34 per share. With cash and equivalents totaling $32.3 million and recent funding of $45.2 million, LogicBio is positioned to sustain operations for at least the next year.
LogicBio Therapeutics announces that the FDA has granted Fast Track designation to its candidate LB-001 for treating methylmalonic acidemia (MMA). This designation aims to accelerate the development of drugs addressing serious conditions and unmet medical needs. LogicBio plans to work closely with the FDA to expedite LB-001's availability. Additionally, the company is developing a Next Generation Capsid platform for gene therapies, and it has FDA clearance for LB-001's clinical trial, with patient enrollment expected to begin in early 2021.